Tag Archives: ELCC

April, 2016

  • 15 April

    Plasma Genotyping to Predict Treatment Benefit in Patients with NSCLC

    GENEVA, Switzerland, 15 April 2016 – The benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer (NSCLC) is confirmed in three studies presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.1 Researchers however warned that plasma tests are unlikely to fully …

  • 15 April

    Ariad Presents Updated Phase 1/2 Data on its NSCLC Drug

    GENEVA & CAMBRIDGE, Mass.–(BUSINESS WIRE)–ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical data on its investigational tyrosine kinase inhibitor, brigatinib, in patients with advanced malignancies, including anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC), from an ongoing Phase 1/2 trial. This report includes updated data on the …